StocksMedium•9 November 2026•
1 min read
Bicara Therapeutics Reports Q3 2026 Results and Clinical Trial Progress
Key Facts
1Bicara Therapeutics announced financial results for the third quarter ended September 30, 2026, alongside clinical trial updates.
2The company achieved substantial enrollment in the FORTIFI-HN01 pivotal trial, with topline results expected in mid-2027.
Bicara Therapeutics announced financial results for the third quarter ended September 30, 2026, alongside clinical trial updates. The company reported in a GlobeNewswire statement that it achieved substantial enrollment in the FORTIFI-HN01 pivotal trial, with topline results from the interim analysis expected in mid-2027.
BCAX closed at $8.65 on November 6, 2026, with the stock trading between a day low of $8.06 and a high of $8.93 during that session. The company is currently focusing on the development of ficerafusp alfa, including the FORTIFI-FLEX study to evaluate dosing regimens, alongside its third-quarter financial and operational progress.